Daniel Drucker, a Canadian endocrinologist and Nobel Prize nominee, received the Frontiers of Knowledge Prize for his work on glucagon-like peptide (GLP-1). His research contributes to the popular diabetes drug Ozempic, which has gained notoriety for its weight-loss effects. Drucker observes that the societal hype surrounding Ozempic sometimes feels excessive. He recognizes the potential misuse of the drug but emphasizes the importance of this research in providing effective weight management therapies for those previously lacking options.
It's sometimes excessive. When I go out in the world, if I go to the store, if I go to a football match, if I turn the television on, all I see is Ozempic, everywhere.
But I also think it's an opportunity to show the importance of science and the importance of being able to help people living with obesity that didn't have good therapies before.
Collection
[
|
...
]